Yeah, fair enough. I think I should have worded that a little different. I think it's good to see the company with a drug already approved and on the market with this MoA, Genzyme, sees the utility in further expanding the testing of this kind of drug in oncology. It gives me more confidence in BLRX's chances than had there been no drug with this MoA on the market at all.
Is a small molecule more preferable than a peptide in this type of setting?